Company profile
Ticker
ANRO
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Alto Neuroscience (Australia) Pty Ltd ...
IRS number
834210124
ANRO stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
21 Mar 24
8-K
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
21 Mar 24
8-K
Departure of Directors or Certain Officers
11 Mar 24
S-8
Registration of securities for employees
6 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
6 Feb 24
424B4
Prospectus supplement with pricing info
5 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
SEC STAFF
SEC staff action: Order
2 Feb 24
S-1MEF
Registration of additional securities for an S-1
1 Feb 24
CERT
Certification of approval for exchange listing
30 Jan 24
Latest ownership filings
4
Nicholas Conrad Smith
1 Apr 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
29 Mar 24
4
Maha Radhakrishnan
12 Mar 24
3
Maha Radhakrishnan
12 Mar 24
4
Christian Angermayer
6 Mar 24
4
Adam Savitz
5 Mar 24
4
Nicholas Conrad Smith
5 Mar 24
4
Amit Etkin
5 Mar 24
SC 13G
Alpha Wave Global, LP
9 Feb 24
4
Change in insider ownership
8 Feb 24
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | Nicholas Conrad Smith | Common Stock | Buy | Acquire P | No | No | 16.56 | 4,550 | 75.35 k | 26,866 |
28 Mar 24 | Nicholas Conrad Smith | Common Stock | Buy | Acquire P | No | No | 15.8 | 1,600 | 25.28 k | 22,316 |
8 Mar 24 | Maha Radhakrishnan | Stock Option Common Stock | Grant | Acquire A | No | No | 10.213 | 1,590 | 16.24 k | 1,590 |
8 Mar 24 | Maha Radhakrishnan | Stock Option Common Stock | Grant | Acquire A | No | No | 13.76 | 30,574 | 420.70 k | 30,574 |
1 Mar 24 | Adam Savitz | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 14.88 | 73,000 | 1.09 mm | 73,000 |
1 Mar 24 | Nicholas Conrad Smith | Common Stock | Grant | Acquire A | No | No | 0 | 19,153 | 0.00 | 20,716 |
1 Mar 24 | Nicholas Conrad Smith | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 14.88 | 90,000 | 1.34 mm | 90,000 |
News
Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape
23 Apr 24
Stifel Reiterates Buy on Alto Neuroscience, Maintains $32 Price Target
25 Mar 24
Stifel Initiates Coverage On Alto Neuroscience with Buy Rating, Announces Price Target of $32
27 Feb 24
Jefferies Initiates Coverage On Alto Neuroscience with Buy Rating, Announces Price Target of $33
27 Feb 24
Baird Initiates Coverage On Alto Neuroscience with Outperform Rating, Announces Price Target of $32
27 Feb 24
Press releases
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
23 Apr 24
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
3 Apr 24
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
21 Mar 24
Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
6 Feb 24
Alto Neuroscience Announces Pricing of Upsized Initial Public Offering
1 Feb 24